FDA Investigation into Schizophrenia Drug Deemed Inconclusive


Zyprexa Relprevv's label and recommended use remain unchanged.

The FDA’s review of 2 patient deaths associated with Lilly’s injectable schizophrenia drug, olanzapine pamoate (Zyprexa Relprevv), produced inconclusive results, leaving the drug’s label and recommended use unchanged.

However, the FDA could not exclude the possibility that the deaths were caused by the drug’s rapid yet delayed entry into the bloodstream. The data indicated that the elevated drug levels could have occurred after death, as both patients died 3 to 4 days after receiving the appropriately dosed injections.

Based on these data, the FDA has not altered Zyprexa Relprevv’s label and is not recommending any changes to the prescribing or use of the drug.

The FDA advised health care professionals to continue to follow the Zyprexa Relprevv Patient Care Program Risk Evaluation and Mitigation Strategy requirements and current label recommendations. The agency also noted that patients should not stop receiving treatment without consulting their health care professional first.

Zyprexa Relprevv currently carries a boxed warning for post-injection delirium sedation (PDSS), and the FDA said those receiving the drug should immediately report PDSS symptoms to a health care professional.

Related Videos
Pride flags during pride event -- Image credit: ink drop | stock.adobe.com
Female Pharmacist Holding Tablet PC - Image credit: Tyler Olson | stock.adobe.com
African American male pharmacist using digital tablet during inventory in pharmacy - Image credit: sofiko14 | stock.adobe.com
Young woman using smart phone,Social media concept. - Image credit: Urupong | stock.adobe.com
selling mental health medication to man at pharmacy | Image Credit: Syda Productions - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Image credit: rawpixel.com | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.